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MEETING SUMMARY
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BACKGROUND & AIMS: Therapeutic drug monitoring (TDM) is widely available for biologic therapies in patients
with inflammatory bowel disease (IBD). We reviewed current data and provided expert
opinion regarding the clinical utility of TDM for biologic therapies in IBD.
METHODS: We used a modified Delphi method to establish consensus. A comprehensive literature re-
view was performed regarding the use of TDM of biologic therapy in IBD and presented to
international IBD specialists. Subsequently, 28 statements on the application of TDM in
clinical practice were rated on a scale of 1 to 10 (1 [ strongly disagree and 10 [ strongly
agree) by each of the panellists. Statements were accepted if 80% or more of the participants
agreed with a score ‡7. The remaining statements were discussed and revised based on the
available evidence followed by a second round of voting.
RESULTS: The panel agreed on 24 (86%) statements. For anti-tumor necrosis factor (anti-TNF) ther-
apies, proactive TDM was found to be appropriate after induction and at least once during
maintenance therapy, but this was not the case for the other biologics. Reactive TDM was
appropriate for all agents both for primary non-response and secondary loss of response.
The panellists also agreed on several statements regarding TDM and appropriate drug and
anti-drug antibody (ADA) concentration thresholds for biologics in specific clinical
scenarios.
CONCLUSION: Consensus was achieved towards the utility of TDM of biologics in IBD, particularly anti-TNF
therapies. More data are needed especially on non-anti-TNF biologics to further define
optimal drug concentration and ADA thresholds as these can vary depending on the ther-
apeutic outcomes assessed.
Keywords: Consensus Statement; Crohn’s Disease; Ulcerative Colitis; Immunogenicity; Anti-TNF; Vedolizumab;
Ustekinumab.
aAuthors share co-first authorship.
Abbreviations used in this paper: ADA, anti-drug antibodies; ATI, anti-
bodies to infliximab; CD, Crohn’s disease; ELISA, enzyme-linked immu-
nosorbent assay; HMSA, homogeneous mobility shift assay; IBD,
inflammatory bowel disease; PD, pharmacodynamics; PK, pharmacoki-
netic; PNR, primary non-response; RCT, randomized controlled trial; SLR,
secondary loss of response; TDM, therapeutic drug monitoring; TNF, tu-
mor necrosis factor; UC, ulcerative colitis.
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Biologic therapies, including the anti–tumor necrosisfactor (anti-TNF) agents (infliximab, adalimumab,
certolizumabpegol, and golimumab), the adhesionmolecule
inhibitors (vedolizumab and natalizumab), and the p-40
interleukin 12/23 inhibitor ustekinumab, are effective
treatments for patients with moderate to severe inflamma-
tory bowel disease (IBD).1,2 Nevertheless, up to one-third of
patients with Crohn’s disease (CD) and ulcerative colitis
(UC) show primary non-response (PNR) to biologic thera-
pies, and up to 50% of patients after an initial clinical
response stop therapy for either secondary loss of response
(SLR) or a serious adverse event.3,4 Both PNR and SLR are
due to either pharmacokinetic (PK) or pharmacodynamic
(PD) problems. PK issues are associated with inadequate
drug exposure, often because of the development of anti-
drug antibodies (ADA), whereas PD issues are typically
related to inflammatory process unrelated to the targeted
immunoinflammatory pathway.5,6
Numerous studies have demonstrated a positive cor-
relation between serum biologic drug concentrations and
favorable therapeutic outcomes, whereas low or unde-
tectable drug concentrations can lead to immunogenicity
and treatment failure (Tables 1–3, Supplementary
Table 1).7–95 Therapeutic drug monitoring (TDM),
defined as the assessment of drug concentrations and
ADA, is an important tool for optimizing biologic therapy.
Reactive TDM has rationalized the management of PNR
and SLR and has proven more cost-effective when
comparedwith empiric dose escalation.96–102 Preliminary
data suggest that proactive TDM, with drug titration to a
target trough concentration, performed in patients with
clinical response/remission can also improve the efficacy
of anti-TNFs.38,39,103,104 Moreover, proactive TDM may
also improve the cost-effectiveness and safety of biologic
therapy via the implementation of a de-escalation strategy
in patients with supratherapeutic drug concentrations by
reducing the dose, increasing the time interval, and/or
stopping the immunomodulator in patients on combina-
tion therapy (optimized monotherapy).39,82,105–107
However, there are still some limitations when
applying TDM into clinical practice, such as when to use
TDM, proper interpretation and application of the re-
sults, and the identification of the optimal window/
thresholds to target. These therapeutic windows or
thresholds appear to vary on the basis of the outcome of
interest and the IBD phenotype (Tables 1 and 2,
Supplementary Table 1). Moreover, most of the data on
implementation of TDM refer to anti-TNF therapies and
the maintenance phase of treatment.
We aimed to reach a consensus on when and how to
use TDM of biologic therapies during different phases of
the treatment (ie, induction, post-induction, and main-
tenance therapy) and sought to identify clinically rele-
vant drug concentrations and ADA thresholds to help
physicians apply TDM in clinical practice.
Methods
We applied a modified Delphi method to establish
consensus similar to that described in the Selecting Ther-
apeutic Targets in Inflammatory Bowel Disease (STRIDE)
program.108 A comprehensive literature review was per-
formed regarding the use of TDM of biologic therapies in
IBD by using PubMed and Medline databases. We used the
following search terms: “inflammatory bowel disease”;
“Crohn’s disease”; “ulcerative colitis”; “anti-drug anti-
bodies”; “therapeutic drug monitoring” AND “infliximab”
OR “adalimumab” OR “certolizumab pegol” OR “golimu-
mab” OR “vedolizumab” OR “ustekinumab”. The literature
was then presented to a panel of 13 international IBD
specialists. Subsequently, on the basis of this review, 28
statements were formulated (K.P., A.S.C, C.A.S.) describing
when and how to apply TDM in clinical practice. An Expert
Consensus Development Meeting consisting of members of
the BRIDGe group (www.BRIDGeIBD.com) and TDM spe-
cialists was held in New Orleans on December 9, 2017 to
refine and vote anonymously on the statements. Each
statement was rated on a scale of 1–10 (1 ¼ strongly
disagree, 10¼ strongly agree). Statements were accepted if
80% or more of the participants agreed with a score 7. If
less than 80% of the panelists agreed with a score 7,
statements were discussed and revised on the basis of the
available evidence, followed by a second round of voting.
The word appropriate was used for each statement to
suggest that application of TDM for treatment optimization
in a particular clinical scenario is a good option. However,
these are not recommendations applicable to every patient.
Results
The panel reached consensus on 24 of 28 statements
(86%) (Tables 4 and 5).
Scenarios When Therapeutic Drug Monitoring
of Biologic Therapies Should Be Performed
Anti–tumor necrosis factor therapy. On the basis of the
literature review, consensus was reached on all 4 state-
ments regarding anti-TNFs (Table 4).
1. It is appropriate to order drug/antibody concen-
tration testing in responders at the end of induc-
tion for all anti-TNFs.
2. It is appropriate to order drug/antibody concen-
tration testing at least once during maintenance for
patients on all anti-TNFs.
3. It is appropriate to order drug/antibody concen-
tration testing of anti-TNFs at the end of induction
in primary non-responders.
4. It is appropriate to order drug/antibody concen-
tration testing for all anti-TNFs in patients with
confirmed secondary loss of response.
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Numerous studies have demonstrated a positive
correlation between anti-TNF drug concentrations and
favorable therapeutic outcomes (Tables 1 and 2,
Supplementary Table 1). However, the great majority of
TDM studies refer to infliximab. A large retrospective
study showed that at least one TDM, either proactive
and/or reactive of infliximab compared with lack of any
TDM, was associated with less treatment failure.109
Several studies have shown that reactive TDM can bet-
ter identify the cause and consequently manage SLR to
anti-TNF therapy, although the data for PNR are more
scarce.4,5,8,10,110 Reactive TDM to guide infliximab dose
adjustment compared with clinical decision-making
alone is associated with higher post-adjustment clinical
response and endoscopic remission and fewer
hospitalizations.37 Moreover, reactive TDM of infliximab
was found more cost-effective than using clinical symp-
toms alone to guide therapeutic decisions.99,101,102,111
Proactive TDM of infliximab compared with empiric
dose escalation and/or reactive TDM was found to be
associated with increased drug retention.39 The landmark
randomized controlled trial (RCT), Trough Concentration
Adapted Infliximab Treatment (TAXIT), despite failing to
meet its primary endpoint, showed that proactive TDM of
infliximab compared with clinically based dosing was
associated with lower frequency of undetectable drug
concentrations and lower risk of relapse.104 In addition, in
patients with CD and subtherapeutic drug concentrations, a
one-time dose optimization improved clinical remission
rates and C-reactive protein.104 Furthermore, proactive
Table 1. Serum Adalimumab Concentration Thresholds Associated With Therapeutic Outcomes in Inflammatory Bowel
Disease
IBD type Threshold (mg/mL) Therapeutic outcome TDM assay Assay type Reference
Induction (week 2)
CD >6.7 Clinical remission (w14) ELISA AHLC 23
Post-induction (week 4)
CD >5 Drug retention HMSA Prometheus 29
CD >12 Normal CRP (5 mg/L) ELISA LFA/ELISA (R-Biopharm AG) 31
UC 7.5 Mucosal healing (w10–14) ELISA Leuven assay 30
UC >4.6 Clinical response (w12) ELISA Leuven assay 26
UC >7 Clinical response (w52) ELISA Leuven assay 26
Maintenance
CD >5.9 Normal CRP (5 mg/L) ELISA AHLC 15
CD >5.9 Normal CRP (3 mg/L) ELISA Sumitomo Bakelite Co Ltd 16
CD >8.1 Mucosal healing HMSA Prometheus 18
CD >5.6 Normal CRP (3 mg/L) ELISA In-house 19
CD >7.9 Mucosal healing ELISA In-house 19
CD >10.3 Mucosal healing ELISA In-house 20
CD >5 (w26) Clinical remission (w52) ELISA Sanquin Diagnostics 21
CD 12 Endoscopic remission HMSA Prometheus 22
CD 12.2 Histologic remission HMSA Prometheus 22
CD 3.7 (w14) CRP normalization (w14) ELISA AHLC 23
CD/UC >6.6 Normal CRP (5 mg/L) ELISA AHLC 13
CD/UC 6.9 No SLR RIA Biomonitor A/S 14
CD/UC >7.1 Mucosal healing ELISA AHLC 13
CD/UC >4.9 Mucosal healing ELISA Theradiag 9
CD/UC >7.8 Histologic remission HMSA Prometheus 12
CD/UC >7.5 Mucosal healing HMSA Prometheus 12
CD/UC >12.2 Successful dose reduction ELISA Promonitor Grifols 11
CD/UC >9 Clinical response ELISA Promonitor Grifols 11
CD/UC >6.6 Normal CRP (5 mg/L) ELISA Promonitor Grifols 11
CD/UC >4.5 When SLR, better long-term
outcome when change to a
biological with a different
mechanism of action
compared with anti-TNF
dosage increase or a switch
within class
ELISA AHLC 10
CD/UC 3 No active inflammationa ELISA AHLC 10




CD/UC >7.3 Clinical remission ELISA New Zealand assay 7
AHLC, antihuman lambda chain; CD, Crohn’s disease; CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; HMSA, homogeneous mobility shift
assay; LFA, lateral flow-based assay; RIA, radioimmunoassay; SLR, secondary loss of response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor;
UC, ulcerative colitis; w, week.
aDefined as increased CRP level and/or endoscopic/imaging documentation of inflammation.
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compared with reactive TDM of infliximab was associated
with greater drug durability, less need for IBD-related
surgery or hospitalization, and lower risk of antibodies to
infliximab or serious infusion reactions.38 Recently, proac-
tive after reactive TDM of infliximab was found to be
associated with greater drug persistence and fewer IBD-
related hospitalizations than reactive TDM alone.103 Pro-
active TDM can also efficiently guide immunomodulator
withdrawal in patients on combination therapy. This
concept of optimized monotherapy was introduced in a
retrospective study showing that patients with infliximab
concentrations 5 mg/mL had similar drug persistence
when treated with infliximab monotherapy or combination
therapy with an immunomdulator5 and is further sup-
ported by a recent post hoc analysis of the RCT Study of
Biologic and Immunomodulator Naïve Patients in Crohn’s
Disease (SONIC), which demonstrated that patients strati-
fied by infliximab trough quartiles had comparable out-
comes regardless of concomitant azathioprine.112
Vedolizumab. Consensus was reached on only 2 of 4
statements regarding vedolizumab (Table 4).
7. It is appropriate to order drug/antibody concen-
tration testing for vedolizumab in non-responders
at the end of induction.
8. It is appropriate to order drug/antibody concen-
tration testing for vedolizumab in patients with
confirmed secondary loss of response.
The current evidence supporting the role of TDM
regarding vedolizumab derives only from exposure-
response relationship studies showing that higher
Table 2. Association of Serum Certolizumab Pegol, Golimumab, Vedolizumab, and Ustekimumab Concentration Thresholds
With Therapeutic Outcomes in Inflammatory Bowel Disease




assay Assay type Reference
Certolizumab pegol
CD Post-induction (w6) >31.8 Clinical response/remission (w6) ELISA UCB Pharma 94
CD Post-induction (w6) >31.9 Normal CRP (5 mg/L) (w6) ELISA UCB Pharma 94
CD Post-induction (w6) >32.7 Normal FC (<250 mg/g) (w6) ELISA UCB Pharma 94
CD Post-induction (w6) >34.5 Normal FC (<250 mg/g) and
CDAI (150) (w6)
ELISA UCB Pharma 94
CD Post-induction (w6) >36.1 Normal FC (<250 mg/g) and
CDAI (150) (w26)
ELISA UCB Pharma 94
CD Post-induction (w8) >23.3 Endoscopic remission (w10) ELISA UCB Pharma 95
CD Maintenance (w12) >13.8 Normal FC (<250 mg/g) (w26) ELISA UCB Pharma 94
CD Maintenance (w12) >14.8 Normal FC (<250 mg/g) and
CDAI (150) (w26)
ELISA UCB Pharma 94
Golimumab
UC Induction (w2) >8.9 Clinical response (w6) ECLIA Janssen Biotech Inc 48
UC Post-induction (w4) >7.4 Clinical response (w6) ECLIA Janssen Biotech Inc 48
UC Post-induction (w6) >2.5 Clinical response (w6) ECLIA Janssen Biotech Inc 48
UC Post-induction (w6) >2.6 Partial clinical response (w14) ELISA In-house Leuven 93
UC Maintenance (w28) >0.9 Clinical remission (w30 and 54) ECLIA Janssen Biotech Inc 48
UC Maintenance (w44) >1.4 Clinical remission (w30 and 54) ECLIA Janssen Biotech Inc 48
Vedolizumab
CD Induction (w2) >35.2 Biological remission (w6) ELISA Leuven assay 90
UC Induction (w2) >28.9 Clinical response (w14) ELISA Leuven assay 90
UC Induction (w2) >23.7 Mucosal healing (w14) ELISA Leuven assay 90
CD/UC Induction (w2) 24.5 No drug optimization (within w24) ELISA Theradiag 92
UC Induction (w6) >20.8 Clinical response (w14) ELISA Leuven assay 90
CD/UC Induction (w6) 18.5 No need for extended therapy ELISA Theradiag 92
CD/UC Induction (w6) >27.5 Sustained clinical response ELISA Theradiag 92
CD/UC Induction (w6) >18 Mucosal healing (within w54) ELISA Theradiag 91
UC Post-induction (w14) >12.6 Clinical response (w14) ELISA Leuven assay 90
UC Post-induction (w14) >17 Mucosal healing (w14) ELISA Leuven assay 90
CD Maintenance (w22) >13.6 Mucosal healing (w22) ELISA Leuven assay 90
CD Maintenance (w22) >12 Biological remission (w22) ELISA Leuven assay 90
Ustekinumab
CD Post-induction (w8) >3.3 Clinical remission (w8) ECLIA Janssen Biotech Inc 49
CD Maintenance >4.5 Endoscopic response HMSA Prometheus 89
CD Maintenance (w24)a >0.8 Clinical remission (w24) ECLIA Janssen Biotech Inc 49
CD Maintenance (w40)b >1.4 Clinical remission (w44) ECLIA Janssen Biotech Inc 49
CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CRP, C-reactive protein; ECLIA, electrochemiluminescence immunoassay; ELISA, enzyme-linked
immunosorbent assay; FC, fecal calprotectin; HMSA, homogeneous mobility shift assay; TDM, therapeutic drug monitoring; UC, ulcerative colitis; w, week.
aCombined every 8w and every 12w.
bEvery 8w only.
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Table 3. Association of Anti-Drug Antibodies With Therapeutic Outcomes in Inflammatory Bowel Disease
Drug IBD type ADA Therapeutic outcome TDM assay Assay type Reference
IFX CD 282 ng/mL-eq Lower success rate of treatment
optimization
ELISA Leuven drug-tolerant assay 75
IFX CD >8 mg/mL-eq Shorter clinical response ELISA Prometheus 28
IFX CD Detectable Lack of mucosal healing ELISA MP Biomedicals 17
IFX CD Detectable Elevated CRP (>5 mg/L) HMSA Prometheus 56
IFX CD Detectable Elevated CRP (>5 mg/L) HMSA Prometheus 60
IFX CD Detectable Lack of fistula healing HMSA Prometheus 12
IFX CD Detectable SLR ELISA Prometheus 88
IFX CD Detectable SLR RIA Biomonitor A/S 87
IFX UC Detectable Lack of endoscopic response HMSA Prometheus 33
IFX UC Detectable Lack of mucosal healing ELISA Leuven drug-tolerant assay 67
IFX CD/UC 8.8 U/mL Drug discontinuation HMSA Prometheus 86
IFX CD/UC Detectable PNR ELISA AHLC 73
IFX CD/UC Detectable Drug discontinuation HMSA Prometheus 63
IFX CD/UC >9.1 U/mL Failure of dose intensification after
SLR
HMSA Prometheus 63
IFX CD/UC >12 U/mL Surgery HMSA Prometheus 85
IFX CD/UC Undetectable Mucosal healing ELISA AHLC 13
IFX CD/UC Undetectable Short-term clinical response HMSA Prometheus 27
IFX CD/UC Detectable SLR ELISA AHLC 32
IFX CD/UC Detectable SLR ELISA AHLC 84
IFX CD/UC >9 mg/mL-eq When SLR, longer duration of
response when anti-TNF agents
are switched than when dosage is
increased
ELISA AHLC 10
IFX CD/UC 3.3 U/mL Lack of post-adjustment endoscopic
remission
HMSA Prometheus 37
IFX CD/UC Detectable Treatment-related adverse events ELISA Promonitor Menarini/
ImmunDiagnostik
83
IFX CD/UC Detectablea PNR (w14) ELISA AHLC 73
IFX CD/UC >4.3 mg/mL-eqb PNR (w14) ELISA AHLC 73
IFX CD/UC >9.1 U/mL IFX discontinuation HMSA Prometheus 82
IFX CD/UC >9.1 U/mL Infusion reactions HMSA Prometheus 82
IFX CD/UC >200 ng/mL-eq No response to treatment
optimization
ELISA Theradiag 81
ADM CD Detectable PNR ELISA AHLC 23
ADM CD Detectable Drug discontinuation HMSA Prometheus 29
ADM CD Detectable Drug discontinuation ELISA In-housec 57
ADM CD >12 U⁄ mL Lack of clinical response RIA Biomonitor A/S 58
ADM CD Detectable Active disease ELISA AHLC 15
ADM CD Detectable Higher CRP and ESR ELISA Sumitomo Bakelite Co, Ltd 16
ADM CD Detectabled No clinical remission (w52) RIA Sanquin 21
ADM CD Detectable (w12) Higher needs for dose escalation less
frequently sustained clinical
benefit due to PNR or SLR
ELISA R-Biopharm AG 31
ADM CD/UC Detectable Drug discontinuation RIA Biomonitor A/S 80
ADM CD/UC >4 mg/mL-eq When SLR, longer duration of
response when anti-TNF agents
are switched than when dosage is
increased
ELISA AHLC 10
ADM CD/UC Detectable SLR RIA Biomonitor A/S 14
ADA, anti-drug antibody; ADM, adalimumab; AHLC, antihuman lambda chain antibody; CD, Crohn’s disease; CRP, C-reactive protein; ELISA, enzyme-linked
immunosorbent assay; ESR, erythrocyte sedimentation rate; HMSA, homogeneous mobility shift assay; IFX, infliximab; PNR, primary non-response; RIA,
radioimmunoassay; SLR, secondary loss of response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor; UC, ulcerative colitis; w, week.
aEither week 2 or 6.
bWeek 2.
cUniversité François-Rabelais, Immuno-Pharmaco-Genetics of Therapeutic Antibodies, Tours, France.
dWeek 26.
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vedolizumab concentrations are associated with better
therapeutic outcomes (Table 2).90–92,113 In particular, a
large single-center retrospective cohort study of 179
patients (66 with UC and 113 with CD) showed that
higher vedolizumab trough concentrations at weeks 2
and 6 were associated with a higher probability of
attaining endoscopic healing, clinical response and bio-
logic response, or remission assessed at week 14 for UC
and week 22 for CD.90 A multicenter prospective
observational study identified a vedolizumab trough
concentration cutoff of 18 mg/mL at week 6 as the only
independent variable associated with mucosal healing
within the first year of treatment.91 Currently, there are
no studies comparing either proactive or reactive TDM
with symptom-based vedolizumab optimization.
Ustekinumab. Consensus was reached on only 2 of 4
statements regarding ustekinumab (Table 4).
11. It is appropriate to order drug/antibody concen-
tration testing for ustekinumab in non-
responders at the end of induction (at 8 weeks).
12. It is appropriate to order drug/antibody concen-
tration testing for ustekinumab in patients with
confirmed secondary loss of response.
The current evidence supporting the role of TDM
regarding ustekinumab is based on 2 exposure-response
relationship studies showing that higher ustekinumab
concentrations correlate to better therapeutic outcomes
(Table 2).49,89 At this time, there are still no studies
comparing either proactive or reactive TDM with empiric
ustekinumab optimization.
Assays, Drug Concentrations, and Anti-Drug
Antibodies
General. Consensus was reached on all 4 statements
regarding the use of biologic drug concentrations and
anti-drug antibodies (Table 5).
13. There is no difference in indication for ordering
drug/antibody concentrations or interpretation
of results for biosimilars or originator drug.
Current data suggest that infliximab enzyme-linked
immunosorbent assays (ELISAs) for evaluating either
drug concentrations or antibodies to infliximab (ATI) are
suitable for monitoring the infliximab biosimilars SB2
and CT-P13.114–117
14. The threshold drug concentration may vary
depending on disease phenotype and desired
therapeutic outcome.
Numerous studies have shown an association be-
tween higher induction or maintenance biologic drug
concentrations and favorable therapeutic outcomes in
IBD (Tables 1 and 2, Supplementary Table 1). Current
exposure-response relationship studies suggest that
biologic drug concentration thresholds and ranges
appear to differ depending on treatment goals and/or
disease phenotypes. In general, higher drug concentra-
tions tend to be associated with more stringent out-
comes, and higher drug concentrations appear to be
needed for phenotypes with a higher inflammatory
burden, such as fistulizing CD (Tables 1 and 2,
Supplementary Table 1, Figure 1).
15. In the presence of adequate trough drug con-
centrations, anti-drug antibodies are unlikely to
be clinically relevant.
A study from Steenholdt et al118 showed that most
ATI detected via the drug-tolerant homogeneous
mobility-shift assay (HMSA) lack neutralizing potential
when tested via a functional cell-based reporter-gene
Table 4. Scenarios of Applying Therapeutic Drug Monitoring






1. It is appropriate to order drug/antibody
concentration testing in responders at the end of
induction for all anti-TNFs.
92 (12/13)
2. It is appropriate to order drug/antibody
concentration testing at least once during
maintenance for patients on all anti-TNFs.
100 (13/13)
3. It is appropriate to order drug/antibody
concentration testing of anti-TNFs at the end of
induction in primary non-responders.
100 (13/13)
4. It is appropriate to order drug/antibody
concentration testing for all anti-TNFs in patients
with confirmed secondary loss of response.
100 (13/13)
Vedolizumab
5. It is appropriate to order drug/antibody
concentration testing for vedolizumab in
responders at the end of induction.
15 (2/13)a
6. It is appropriate to order drug/antibody
concentration testing at least once during
maintenance for patients on vedolizumab.
46 (6/13)a
7. It is appropriate to order drug/antibody
concentration testing for vedolizumab in non-
responders at the end of induction.
92 (12/13)
8. It is appropriate to order drug/antibody
concentration testing for vedolizumab in patients
with confirmed secondary loss of response.
83 (10/12)a
Ustekinumab
9. It is appropriate to order drug/antibody
concentration testing for ustekinumab in
responders at the end of induction.
39 (5/13)a
10. It is appropriate to order drug/antibody
concentration testing at least once during
maintenance for patients on ustekinumab.
31 (4/13)a
11. It is appropriate to order drug/antibody
concentration testing for ustekinumab in non-
responders at the end of induction (at 8 weeks).
92 (12/13)
12. It is appropriate to order drug/antibody
concentration testing for ustekinumab in patients
with confirmed secondary loss of response.
83 (10/12)a
TNF, tumor necrosis factor.
aAfter a second round of voting.
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assay, suggesting that they may not be clinically signifi-
cant. A post hoc analysis of the TAXIT study, which
investigated the additional benefit of a drug-tolerant
assay, concluded that although it allowed closer follow-
up of ATI concentrations and identification of true
transient versus persistent antibodies, it offered no
clinical benefit over a drug-sensitive assay.119 Never-
theless, other studies have suggested that “double posi-
tive” patients (with positive ATI and drug on board) may
be prone to SLR or lack of mucosal healing.60,67,120
16. Other than for ATI, there are not enough data to
recommend a threshold for high anti-drug anti-
body titers for the biologic drugs.
Numerous studies have shown that ADA are asso-
ciated with subtherapeutic drug trough concentrations,
loss of response, and lack of recapture of response
after dose escalation (Table 3).10,12–17,21,23,27–29,31–33,
37,56–58,60,63,67,73,75,80–88 However, the great majority
of them and specifically the ones suggesting a
threshold of high-titer ADA refer to ATI (Table 3).
Infliximab. Consensus was reached on all statements
regarding infliximab concentrations and ATI (Table 5).
17. The current evidence suggests that the variability
of infliximab concentrations between the different
assays is unlikely to be clinically significant.
Table 5. Biological Drug Concentrations and Anti-Drug Antibodies When Applying Therapeutic Drug Monitoring in
Inflammatory Bowel Disease
Statement Vote agreement, %
General
13. There is no difference in indication for ordering drug/antibody concentrations or interpretation of
results for biosimilars or the originator drug.
100 (13/13)
14. The threshold drug concentration may vary depending on disease phenotype and desired
therapeutic outcome.
100 (13/13)
15. In the presence of adequate trough drug concentrations, anti-drug antibodies are unlikely to be
clinically relevant.
100 (12/12)
16. Other than for anti-infliximab antibodies, there are not enough data to recommend a threshold for
high anti-drug antibody titers for the biologic drugs.
100 (12/12)
Infliximab
17. The current evidence suggests that the variability of infliximab concentrations between the different
assays is unlikely to be clinically significant.
100 (13/13)a
18. There is insufficient evidence that inter-assay drug concentration results are comparable for
biologic drugs other than for infliximab.
100 (13/13)
19. The minimal trough concentration for infliximab post-induction at week 14 should be greater than 3
mg/mL, and concentrations greater than 7 mg/mL are associated with an increased likelihood of
mucosal healing.
100 (13/13)
20. During maintenance the minimal trough concentration for infliximab for patients in remission should
be greater than 3 mg/mL. For patients with active disease, infliximab should generally not be
abandoned unless drug concentrations are greater than 10 mg/mL.
92 (12/13)
21. In the absence of detectable infliximab, high titer anti-infliximab antibodies require a change of
therapy. Low level antibodies can sometimes be overcome. For the ANSER assay, a high titer anti-
infliximab antibody at trough is defined as 10 U/mL, for RIDAscreen the cutoff is 200 ng/mL, and for
InformTx/Lisa Tracker the cutoff is 200 ng/mL. For other assays, there are insufficient data to define
an adequate cutoff for a high titer anti-infliximab antibody.
100 (13/13)
Adalimumab
22. The minimum drug concentration at week 4 for adalimumab should at least be 5 mg/mL. Drug
concentrations greater than 7 mg/ml are associated with an increased likelihood of mucosal healing.
83 (10/12)a
23. During maintenance the minimum trough concentration for adalimumab for patients in remission
should be greater than 5 mg/mL. For patients with active disease, adalimumab should generally not
be abandoned unless drug concentrations are greater than 10 mg/mL.
100 (12/12)
Certolizumab pegol
24. The minimum concentrations for certolizumab pegol at week 6 should be greater than 32 mg/mL. 100 (12/12)
25. During maintenance the minimum trough concentration for certolizumab pegol for patients in
remission should be 15 mg/mL.
92 (11/12)
Golimumab
26. The minimum drug concentration at week 6 for golimumab should at least be 2.5 mg/mL. 92 (11/12)
27. During maintenance the minimum trough concentration for golimumab for patients in remission
should be greater than 1 mg/mL.
92 (11/12)
Vedolizumab/ustekinumab
28. Although there are emerging data that may show an association between drug concentrations and
outcomes, they are not sufficient to guide specific induction and maintenance drug concentrations
for vedolizumab and ustekinumab other than confirming that there is detectable drug.
100 (12/12)
aAfter a second round of voting.
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18. There is insufficient evidence that inter-assay
drug concentration results are comparable for
biologic drugs other than for infliximab.
Current evidence suggests that although absolute
drug concentrations can differ between different assays,
including the commonly used ELISA, radioimmunoassay,
HMSA, and the recently developed electro-
chemiluminescence immunoassay, they correlate well
and generally lead to the same therapeutic deci-
sion.83,118,121–123 However, these data refer mostly to
infliximab, whereas there are only scarce data for adali-
mumab and none for non–anti-TNF agents.
19. The minimal trough concentration for infliximab
post-induction at week 14 should be greater than
3 mg/mL, and concentrations greater than 7 mg/
mL are associated with an increased likelihood of
mucosal healing.
20. During maintenance the minimal trough concen-
tration for infliximab for patients in remission
should be greater than 3 mg/mL. For patients
with active disease, infliximab should generally
not be abandoned unless drug concentrations are
greater than 10 mg/mL.
These drug concentration thresholds were mainly
based on infliximab exposure-response relationship
studies depicted in Supplementary Table 1.
21. In the absence of detectable infliximab, high-titer
ATI require a change of therapy. Low-level anti-
bodies can sometimes be overcome. For the ANSER
assay, a high-titer ATI at trough is defined as 10 U/
mL, for RIDAscreen the cutoff is 200 ng/mL, and
for InformTx/Lisa Tracker the cutoff is 200 ng/mL.
For other assays, there are insufficient data to
define an adequate cutoff for a high-titer ATI.
Differences in assay methodology result in varying
sensitivity to detect ADA and discrepancies when
reporting ADA titers.122 Therefore, clinically relevant ADA
cutoffs are assay specific, referring mostly to ELISAs and
the HMSA (Table 3). Vande Casteele et al63 showed that
ATI >9.1 U/mL (measured with the HMSA) at time of loss
of response resulted in a likelihood ratio of 3.6 for an
unsuccessful intervention, suggesting these ATI are sus-
tained and probably very hard to overcome. Moreover,
Yanai et al10 showed ATI >9 mg/mL-eq can identify pa-
tients who do not respond to an increased drug dosage
with 90% specificity. In addition, a small retrospective
study of IBD patients in whom infliximab was optimized,
either proactively or reactively, to overcome immunoge-
nicity showed that an ATI titer <8.8 U/mL (measured
with the HMSA) was associated with drug retention,
suggesting that lower-titer ATI can often be overcome
with dose intensification.86 A post hoc analysis of the
TAXIT trial showed that ATI >222 ng/mL-eq (measured
with an in-house developed drug-tolerant ELISA) was not
possible to be overcome after infliximab optimization.119
Adalimumab. Consensus was reached on all 2 state-
ments regarding adalimumab concentrations and anti-
bodies to adalimumab (Table 5).
22. The minimum drug concentration at week 4 for
adalimumab should at least be 5 mg/mL. Drug con-
centrations greater than 7 mg/mL are associated
with an increased likelihood of mucosal healing.
23. During maintenance the minimum trough con-
centration for adalimumab for patients in
Figure 1. (A) Infliximab13,17,20,40–43,45,46,53,55,59–61,64,67 and (B) adalimumab9,11–13,15,16,18–23,30,31 concentration thresholds
associated with biological (based on CRP), biochemical (based on FC), endoscopic, or histologic remission in inflammatory
bowel disease. Box whisker plots show the median (solid line within box), interquartile range (upper and lower box boundaries),
and lower and upper extreme (whiskers). ADM, adalimumab; CRP, C-reactive protein; FC, fecal calprotectin; IFX, infliximab.
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remission should be greater than 5 mg/mL. For
patients with active disease adalimumab should
generally not be abandoned unless drug concen-
trations are greater than 10 mg/mL.
These drug concentration thresholds were based
mainly on adalimumab exposure-response relationship
studies depicted in Table 1.
Certolizumab pegol. Consensus was reached on all 2
statements regarding certolizumab pegol concentrations
and antibodies to certolizumab pegol (Table 5).
24. The minimum concentrations for certolizumab
pegol at week 6 should be greater than 32 mg/mL.
25. During maintenance the minimum trough con-
centration for certolizumab pegol for patients in
remission should be 15 mg/mL.
These drug concentration thresholds were based on
certolizumab pegol exposure-response relationship
studies depicted in Table 2.
Golimumab. Consensus was reached on all 2 state-
ments regarding golimumab concentrations and anti-
bodies to golimumab (Table 5).
26. The minimum drug concentration at week 6 for
golimumab should at least be 2.5 mg/mL.
27. During maintenance the minimum trough con-
centration for golimumab for patients in remis-
sion should be greater than 1 mg/mL.
These drug concentration thresholds were based on
exposure-response relationship studies depicted in Table 2.
Vedolizumab and ustekinumab. Consensus was
reached on the statement regarding vedolizumab and
ustekinumab concentrations and antibodies to vedoli-
zumab or ustekinumab (Table 5).
28. Although there are emerging data that may show
an association between drug concentrations and
outcomes, they are not sufficient to guide specific
induction and maintenance drug concentrations
for vedolizumab and ustekinumab other than
confirming that there is detectable drug.
At the time of the consensus meeting there were only
limited data available from exposure-response relation-
ship studies to suggest a clinically relevant vedolizumab
or ustekinumab (Table 2) threshold or range associated
with favorable therapeutic outcomes.
Discussion
Unlike for rheumatoid arthritis and psoriasis, there
are only a limited number of biologic agents approved
for the treatment of IBD. In addition, current data
demonstrate that patients who fail anti-TNF therapies do
no respond as well to subsequent agents.124,125 Thus,
optimizing the use of biologic therapies is of the utmost
importance. TDM is one strategy to optimize biologics
and maximize their effectiveness. Reactive TDM can
better explain and manage SLR, and there is emerging
evidence that proactive TDM further improves outcomes
and is being used more frequently.126,127
In the recent American Gastroenterological Associa-
tion guidelines, no recommendation was made regarding
proactive TDM of anti-TNFs for patients who have
quiescent disease because of a “knowledge gap”.96
However, the IBD Sydney Organisation and the Austra-
lian Inflammatory Bowel Diseases Consensus Working
Group recommended that in patients in clinical remis-
sion after anti-TNF therapy induction, TDM should be
considered to guide management, and also TDM should
be considered periodically in patients in clinical remis-
sion if the results are likely to impact management.97
Although well-designed large prospective studies are
lacking, there are preliminary data mainly from retro-
spective studies that demonstrate that proactive TDM is
associated with better therapeutic outcomes compared
with empiric dose optimization and/or reactive
TDM.38,39,103,104,128 Furthermore, numerous retrospec-
tive studies23,24,26,29,31–33,67,73,74,77–79,129,130 and some
post hoc analyses of RCTs47–49,71,76,94,131,132 have shown
that higher biologic drug concentrations are associated
with favorable short-term and long-term therapeutic
outcomes in IBD (Supplementary Table 1, Tables 1 and
2). There do appear to be certain clinical scenarios that
proactive TDM of anti-TNF therapy can efficiently guide
therapeutic decisions, such as treatment de-escala-
tion,133 the application of optimized monotherapy
instead of combo therapy with immunomodulator,82
restarting therapy after a long drug holiday,27 and
treatment cessation on deep remission.50,51
Nevertheless, before TDM can be widely applied in
clinical practice, there are several obstacles to their
regular use including when to use TDM, how to accu-
rately interpret and apply the results of such testing, and
in defining the optimal drug concentration thresholds
and ranges to target.134 We believe these consensus
statements help address these issues and hope they will
aid physicians in better understanding and using TDM.
Major limitations of the evidence and consequently
these consensus statements relate to the lack of large
prospective studies and RCTs on TDM of biologic therapy
applied on different IBD phenotypes and sparse data on
induction therapy and on biologic agents other than
infliximab and adalimumab. Moreover, it is unclear
whether trough concentrations are the best predictor of
initial response to biologics, compared with peak drug
concentrations or total drug exposure. However, in the
absence of RCTs, consensus guidelines synthesizing the
literature and extrapolating from available data serve to
support clinicians in clinical decision-making.
Further RCTs to establish the utility of proactive TDM,
particularly during the induction phase, should be per-
formed. Additional future directions should include the
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development of accurate, easily accessible, and afford-
able rapid assays and dashboards to allow fast dosing
adaptation and incorporation of predictive PK models
based on patient and disease characteristics.66,135
In conclusion, there is a growing body of evidence
that demonstrates the clinical utility of TDM of biologic
therapy in IBD. This is a big step toward personalized
medicine and optimizing the care of patients with IBD.
Although more prospective data are needed especially
for proactive TDM, induction therapy, and non–anti-TNF
biologics, these consensus statements provide a practical
guide to apply TDM for optimizing biologic therapy in
patients with IBD.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2019.03.037.
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Supplementary Table 1. Serum Infliximab Concentration Thresholds Associated With Therapeutic Outcomes in Inflammatory Bowel Disease
IBD type Time point Threshold (mg/mL) Therapeutic outcome TDM assay Assay type Reference
Induction
CD w2 >16.9a Clinical response (w14) ELISA Theradiag 77
CD w2 >9.2 Clinical remission (w14) ELISA AHLC 24
CD w2 >23.1 Endoscopic remission (w12) ELISA Leuven assay 76
CD w2 >20.4a Clinical remission (w14) ELISA Theradiag 77
CD w2 >9.2 Fistula response (w14) ELISA AHLC 74
CD w2 >9.2 Fistula response (w30) ELISA AHLC 74
UC w2 >21.3 Clinical remission (w14) ELISA Mitsubishi Tanabe Pharma Corp 78
UC w2 28.3 Mucosal healing (w10–14) ELISA Leuven drug-tolerant assay 67
UC w2 <16.5 Colectomy ELISA Leuven assay 79
UC w2 >11.5a Clinical response (w14) ELISA Theradiag 77
UC w2 >11.5a Clinical response (w30) ELISA Theradiag 77
UC w2 >15.3a Clinical remission (w14) ELISA Theradiag 77
UC w2 >14.5a Clinical remission (w30) ELISA Theradiag 77
UC w2 18.6 MES <2 (w8) ELISA Janssen Biotech Inc 132
CD/UC w2 <6.8 PNR (w14) ELISA AHLC 73
CD w6 >10 Endoscopic remission (w12) ELISA Leuven assay 76
CD w6 >7.2 Fistula response (w14) ELISA AHLC 74
CD w6 >8.6 Fistula response (w30) ELISA AHLC 74
CD w6 >2.2 Drug retention beyond 1 year of
treatment
ELISA AHLC 24
UC w6 15 Mucosal healing (w10–14) ELISA Leuven drug-tolerant assay 67
UC w6 >6.6 Endoscopic response (w8) ELISA Sanquin Diagnostics 33
UC w6 >22 Clinical response (w8) ELISA Janssen Biotech Inc 47
CD/UC w6 <3.5 PNR (w14) ELISA AHLC 73
CD/UC w6 <13 ATI formation HMSA Prometheus 63
Post-induction
UC w8 >41.1 Clinical response (w8) ELISA Janssen Biotech Inc 47
CD w10 9.1 Drug retention (w52) HMSA Prometheus 72
CD w14 >12.7 Fistula response (w24) ELISA Dynacare Laboratories 36
CD w14 >3.5 Clinical response (w54) ELISA Janssen Biotech Inc 71
CD w14 <1 SLR (w54) ELISA Janssen Biotech Inc 70
CD w14/22 >3 Sustained clinical response ELISA Matriks Biotek 69
UC w14 >2.5 Colectomy-free survival ELISA In-house Leuven 68
UC w14 2.1 Mucosal healing (w10–14) ELISA Leuven drug-tolerant assay 67
UC w14 2.1 Mucosal healing (w10–14) LFA R-Biopharm AG 66
UC w14 >5.1 Clinical response (w30) ELISA Janssen Biotech Inc 47
UC w14 >3.2a Mucosal healing ELISA Theradiag/Matriks Biotek 65
UC w14 >3.2a Steroid-free remission ELISA Theradiag/Matriks Biotek 65
CD/UC w14 >5.5 Clinical remission (w54) HMSA Prometheus 64
CD/UC w14 <2.2 Treatment failure HMSA Prometheus 63
CD/UC w14 <6.2 Loss of response (w48) HMSA Prometheus 62
Maintenance
















Supplementary Table 1. Continued
IBD type Time point Threshold (mg/mL) Therapeutic outcome TDM assay Assay type Reference
CD >2.8 Normal CRP (5 mg/L) HMSA Prometheus 60
CD 2.2 Normal CRP (5 mg/L) HMSA/ELISA Prometheus 59
CD 9.7 Endoscopic remission HMSA/ELISA Prometheus 59
CD 9.8 Histologic remission HMSA/ELISA Prometheus 59
CD >0.6 Normal CRP (0.3 mg/dL) ELISA MP Biomedicals 17
CD >1.1 Normal FC (<300 mg/g) ELISA MP Biomedicals 17
CD >4 Mucosal healing ELISA MP Biomedicals 17
CD <3 Mean CDAI increase 70 HMSA Prometheus 56
CD >2.7 Mucosal healing ELISA In-house 20
CD >1.5 Clinical remission ELISA Theradiag 55
CD >3.4 Normal CRP (5 mg/L) ELISA Theradiag 55
CD >5.7 Normal FC (<59 mg/g) ELISA Theradiag 55
CD <1.8 Significant endoscopic recurrence ELISA AHLC/Theradiag 54
CD >10.1 Fistula healing HMSA Prometheus 53
CD >10.1 Mucosal healing HMSA Prometheus 53
CD 2.5 Relapse after anti-TNF withdrawal ELISA Matriks Biotek 52
CD 6 Relapse after anti-TNF withdrawal ELISA Leuven assay 51
CD 2 Relapse after anti-TNF withdrawal ELISA In-houseb 50
UC w30 >2.4 Clinical response (w54) ELISA Janssen Biotech Inc 47
UC >3 Normal FC (<250 mg/g) ELISA LFA Bühlmann/Sanquin 46
UC >3 Mucosal healing ELISA LFA Bühlmann/Sanquin 46
UC 7.5 Endoscopic healing HMSA/ELISA Prometheus 45
UC 10.5 Histologic healing HMSA/ELISA Prometheus 45
CD/UC <0.5 SLR RIA Biomonitor A/S 44
CD/UC >6.8 Normal CRP (5 mg/L) ELISA AHLC 13
CD/UC >5 Mucosal healing ELISA AHLC 13
CD/UC >7.3 Normal FC (<250 mg/g) ELISA Immunodiagnostik 43
CD/UC >8.3 Mucosal healing HMSA Prometheus 42
CD/UC >4.1 Clinical remission ELISA In-house 41
CD/UC >2.1 Clinical remission ELISA Theradiag 40
CD/UC >2.9 Clinical remission and normal CRP (5
mg/L)
ELISA Theradiag 40
CD/UC >3.9 Clinical remission and normal FC (<250
mg/g)
ELISA Theradiag 40
CD/UC >4.9 Clinical remission, normal CRP (5 mg/
L) and normal FC (<50 mg/g)
ELISA Theradiag 40
CD/UC 5 Drug retention ELISA/HMSA Prometheus 39
CD/UC <3.5 Treatment failure HMSA Prometheus 38
CD/UC <4.6 IBD-related hospitalization HMSA Prometheus 38
CD/UC <1.8 Detectable ATI HMSA Prometheus 38
CD/UC <6.3 Serious infusion reaction HMSA Prometheus 38
CD/UC >3.8 When SLR, better long-term outcome
when change to a biological with a





















compared with anti-TNF dosage
increase or a switch within class
CD/UC 4.5 Post-adjustment endoscopic remission HMSA Prometheus 37
CD/UC >5 Lower risk for an IBD-related surgery and
dose escalation or drug cessation for
SLR after withdrawal of the
immunomodulator
ELISA Leuven assay 35
CD/UC <3 ATI formation ELISA Sanquin Diagnostics 34
CD/UC >5.1 Clinical remission ELISA New Zealand assay 7
CD/UC >5.4 Endoscopic remission ELISA Leuven 25
AHLC, antihuman lambda chain antibody; ATI, antibodies to infliximab; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; FC, fecal calprotectin;
HMSA, homogeneous mobility shift assay; IBD, inflammatory bowel disease; LFA, lateral flow-based assay; MES, Mayo endoscopic score; PNR, primary non-response; RIA, radioimmunoassay; SLR, secondary loss of
response; TDM, therapeutic drug monitoring; TNF, tumor necrosis factor; UC, ulcerative colitis; w, week.
aInfliximab biosimilar CT-P13.
bUniversité François-Rabelais, Immuno-Pharmaco-Genetics of Therapeutic Antibodies, Tours, France.
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